ClinicalTrials.gg
RecruitingNCT06705257[PEOPLE]Updated May 6, 2026

PEEP FOR LUNG RECRUITMENT IN PRETERM INFANTS-EIT STUDY

An interventional study of Studying the effects of varying levels of PEEP using Electrical impedance tomography in PreTerm Neonate, Positive End Expiratory Pressure (PEEP) and Lung Recruitment, sponsored by South Tees Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 22 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by South Tees Hospitals NHS Foundation Trust · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
22 Weeks to 32 Weeks
Sex
All
01

Study summary

Babies born early (under 32 weeks) are at risk of developing lung problems after birth. A major reason for this is that the lungs are not fully developed. Lungs of preterm babies will often collapse in between breathing due to lung immaturity. Applying gentle pressure, using nasal device through their nostril or through the breathing tube helps to prevent this lung collapse. This would help in air-oxygen going to lungs and also makes the babies breathing more comfortable. This gentle pressure is medically called as PEEP/CPAP and could be delivered by breathing machine (ventilator) and CPAP machine, collectively called as "continuous distending pressure (CDP)".

Those babies breathing on their own and receiving inadequate CDP would need more breathing support by placing them on breathing machine (ventilator). The longer the baby receives breathing machine support, higher chance of lung injury . Preterm infants who are already on breathing machine, providing sub optimal PEEP/CPAP could also lead to lung damage. Providing optimal PEEP/CPAP could prevent these negative outcomes. Currently there is not enough evidence to suggest optimal PEEP/CPAP in preterm infants. Neonatal units all around the world uses PEEP/CPAP ranging from 4 to 10cm H20 based on their unit practice. Currently available investigations provide limited one time information (e.g. Chest X-ray) regarding whether baby is receiving optimal PEEP/CPAP. Electrical Impedance Tomography (EIT) is a new technology which could provide better information regarding the pressure delivered. Also, this device would provide continuous information as if the clinicians are doing continuous chest X-ray but without any radiation. In this study, the team will assess the effect of different levels of PEEP/CPAP (4 to 10cm H20) on prevention of lung collapse using EIT. This would be studied in premature infants who are on breathing machine support and CPAP machine support.

02

Conditions studied

  • PreTerm Neonate
  • Positive End Expiratory Pressure (PEEP)
  • Lung Recruitment
  • Electrical Impedance Tomography (EIT)

Browse trials for

Keywords

  • positive end expiratory pressure
  • PRETERM
  • Electrical Impedance Tomography
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 30 is below the median of 84 across 1,666 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

South Tees Hospitals NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gestational age \<32 weeks based on mother's last menstrual period or first trimester ultrasound dating.
  2. Receiving either CPAP or mechanical ventilation respiratory support.
  3. Informed written consent from one of the parents.
  4. Within the first two weeks of life. Investigators pragmatically chose this period, as there could be considerable lung injury after the first two weeks of life, making it difficult to test our hypothesis. Also, this time period would allow parents to settle down with their stressful preterm delivery and investigators could approach anytime within the first two weeks of life.

Exclusion criteria

Exclusion criteria

  1. Major congenital malformations including congenital lung disease and congenital heart disease as ascertained by the medical team.
  2. Infants diagnosed with pneumothorax i.
  3. Receiving high frequency mechanical ventilation.
  4. Infants with concerns of skin integrity.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Single arm with increasing and decreasing PEEP levels

    Diagnostic Test: Studying the effects of varying levels of PEEP using Electrical impedance tomography

Interventions

  • Diagnostic testStudying the effects of varying levels of PEEP using Electrical impedance tomography

    Feasibility of using EIT, to study the effect of varying levels of PEEP/Continous distending pressure on lung recruitment as measured by changes in functional lung scores and silent spaces in preterm infants (\<32 weeks) who are on mechanical ventilation or receiving primary or post extubation CPAP support.

06

What researchers measure

Primary outcomes

  1. Changes in EIT parameters

    Changes in End expiratory Lung Impedance scores

    Time frame: total study of 280 minutes

  2. Changes in EIT parameters

    Changes in functional lung scores in percentage varying levels of CDP.

    Time frame: 280minutes

  3. Changes in EIT

    Changes in silence spaces with varying levels of CDP.

    Time frame: 280 minutes

Secondary outcomes

  1. Secondary outcomes

    Changes in oxygen saturation (SpO2 in percentage) during the study period.

    Time frame: Total 280 minutes of study time

  2. Secondary outcome measure

    Changes in carbon dioxide levels as measured by transcutaneous carbon dioxide levels (TCO2) in kilopascal.

    Time frame: Total study time of 280 minutes

  3. Secondary outcome

    Changes in fraction of inspiratory oxygen (Fio2) levels during the study.

    Time frame: Total study time of 280 minutes

  4. Secondary outcome

    Changes in blood pressure (if measured) during the study procedure.

    Time frame: Total study time of 280minutes

07

Study locations

1 of 1 sites recruiting
  • South Tees NHS Trust
    Middlesbrough, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After the main study publication

Access criteria: With valid study protocol and ethical approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 741 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 759 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 26, 2024
StartActual
Jun 15, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06705257
Lead sponsor
South Tees Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Jun 15, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Prakash Kannan Loganathan, MD
Contact
pkannanloganathan@nhs.net
+447481492632
Amanda Forster
Contact
amanda.forster2@nhs.net
+44 1642 854872
Jackie Mitchell
study director · South Tees NHS foundation trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion